Use of Direct Oral Anticoagulants in Patients with Antiphospholipid Syndrome

Lupus Anticoagulant (LA)/Antiphospholipid Antibodies (aPL) Subcommittee

Person responsible (Chair / Principal Investigator): Katrien Devreese, Stéphane Zuily and Hannah Cohen

Description Abstract

Clarity and guidance is required with regard to direct oral anticoagulants (DOACs) use in antiphospholipid syndrome (APS) patients, within the confines of the recent European Medicines Agency (EMA) recommendations and the limited evidence base. To address this, the Lupus Anticoagulant (LA)/Antiphospholipid Antibodies (aPL) Scientific and Standardization Committee (SSC) chair and co-chairs propose that they write guidance for physicians to help them manage APS patients. This guidance will also serve as a call and focus for research. Despite conflicting data (EMA recommendations, EULAR guidelines), the document provided by the SSC LA/aPL of the ISTH will give clarity and guidance to physicians based on all available evidence. Uncertainty in this field will be addressed.

Furthermore, this guidance document will also serve as a call and focus for research: Of note, no one has ever looked at the use of high-intensity DOACs to determine whether the thrombotic recurrence rate is lower than that seen with VKAs. In this regard, the RISAPS trial is investigating the use of high-intensity rivaroxaban 15mg twice daily vs warfarin, target INR 3.5 in APS patients with stroke or other ischaemic brain damage. [https://doi.org/10.1186/ISRCTN10280992](https://doi.org/10.1186/ISRCTN10280992). Furthermore, physicians will be asked to follow up prospectively, within a Registry (separate ISTH project) all patients on DOACs as this could help to identify those that could benefit from DOACs; and to consider the potential for other DOAC studies.

Design and methodology (Data expected to collect, sample size and statistical analysis): The Subcommittee will work with the Control of Anticoagulation Subcommittee on a joint guidance document.

Study population (Inclusion, exclusion, eligibility) (patient population; recruitment of participating institutions/physicians and subjects; minimum number needed; expected number): Not applicable.

Expected timeline:

Project was approved by the Guidance and Guidelines Committee in August 2019
SSC Subcommittee Project/Collaborative Project

Submission of the manuscript is expected by November 2019

Expected outcomes (ie. publications): Guidance statement

Publication type (SSC Communication, Guidance document or original article): Guidance document

Description of project set/up and management, needed infrastructure and resources (summary): Not applicable.

Possible references:


